LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
STANDARD BIOTOOLS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.64+0.01 (+2.27%)
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Share price
−$0.6267 (−49.35%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
STANDARD BIOTOOLS INC. saw revenue fall 4.8% to $84.60M over the twelve months to Jun 30, 2026. Free cash flow was -$82.58M.
Revenue
$84.60M
-4.8% vs. a year earlier
Operating income
-$95.47M
TTM Q2 2026
Free cash flow
-$82.58M
TTM Q2 2026
EPS, diluted
$0.22
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $251.45M
- P/E ratio
- 2.9
- Price to sales
- 2.97
- Price to book
- 0.47
- Dividend yield
- –
- Free cash flow yield
- -32.84%
Fundamentals
- Revenue
- $84.60M
- Net income
- $84.91M
- EPS, diluted
- $0.22
- Free cash flow
- -$82.58M
- Book value per share
- $1.38
- Diluted shares
- 391M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$84.60M-4.8% YoY
Gross profit
$42.71M-5.4% YoY
Operating income
-$95.47M
Net income
$84.91M
EPS, diluted
$0.22
Free cash flow
-$82.58M
Reported periodTrailing twelve months